anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Understanding the cause vs consequence relationship of gut inflammation and microbial dysbiosis in inflammatory bowel diseases (IBD) requires a reproducible mouse model of human-microbiota-driven experimental colitis.
RESULTS: Our study demonstrated that human fecal microbiota transplant (FMT) transfer efficiency is an underappreciated source of experimental variability in human microbiota-associated (HMA) mice. Pooled human IBD patient fecal microbiota engrafted germ-free (GF) mice with low amplicon sequence variant (ASV)-level transfer efficiency, resulting in high recipient-to-recipient variation of microbiota composition and colitis severity in HMA Il-10-/- mice. In contrast, mouse-to-mouse transfer of mouse-adapted human IBD patient microbiota transferred with high efficiency and low compositional variability resulting in highly consistent and reproducible colitis phenotypes in recipient Il-10-/- mice. Engraftment of human-to-mouse FMT stochastically varied with individual transplantation events more than mouse-adapted FMT. Human-to-mouse FMT caused a population bottleneck with reassembly of microbiota composition that was host inflammatory environment specific. Mouse-adaptation in the inflamed Il-10-/- host reassembled a more aggressive microbiota that induced more severe colitis in serial transplant to Il-10-/- mice than the distinct microbiota reassembled in non-inflamed WT hosts.
CONCLUSIONS: Our findings support a model of IBD pathogenesis in which host inflammation promotes aggressive resident bacteria, which further drives a feed-forward process of dysbiosis exacerbated by gut inflammation. This model implies that effective management of IBD requires treating both the dysregulated host immune response and aggressive inflammation-driven microbiota. We propose that our mouse-adapted human microbiota model is an optimized, reproducible, and rigorous system to study human microbiome-driven disease phenotypes, which may be generalized to mouse models of other human microbiota-modulated diseases, including metabolic syndrome/obesity, diabetes, autoimmune diseases, and cancer. Video Abstract.
Over the years, survival of children with chronic diseases has significantly improved and a large proportion of them now are entering into adulthood. Transition of Care (ToC) of such patients with having childhood onset of chronic diseases to the adult health care system is well organized in developed countries, although it is an emerging concept in India. In situations where the systems for ToC are not in place, such cases are fraught with unsatisfactory health outcomes. With proper ToC in place, these patients are likely to receive uninterrupted care by the adult care physicians and hence reach their full potential. This document highlights the need, rationale and way forward for ToC of youth with special health care needs (YSHCN) across the country. It also describes the standard operating procedures to develop the ToC at a hospital level for clinicians and administrators.
FIELD: medicine. SUBSTANCE: method deals with enteral injection of porous carrier-sorbent of medicinal preparation into gastrointestinal tract with bifidobacterin. It differs by the fact that, beforehand one should enterally inject porous carrier-sorbent with medicinal preparation inside containing ozonides of triacylglycerols of vegetable oils. The present method enables to shorten therapy terms. EFFECT: higher efficiency of therapy. 3 cl, 1 ex
The invention relates to an application of an anti-dandruff oil-control composition in preparing a hair-washing and hair-care product and the hair-washing and hair-care product. The anti-dandruff oil-control composition is added into a hair-washing and caring product, and the addition amount is 1-10%. The anti-dandruff oil control composition comprises the following components in percentage by weight: 55-75% of solvent, 5-32% of penetration enhancer, 2-10% of active ingredient A and 10-25% of active ingredient B. The active component A has excellent antibacterial performance, oxidation resistance and corrosion resistance, plays roles of relieving itching, controlling oil, reducing skin desquamation and improving skin barrier function on head oil, dandruff and the like; the active component B has good antibacterial performance, can remove biological film, reduce inflammatory reaction, obviously improve oily scalp and strengthen the barrier function of scalp. The components in the invention are compounded, can be mutually synergistic, and is beneficial to repairing and conditioning scalp skin. The anti-dandruff and oil-control composition can be applied to shampoo, hair conditioner and scalp essence products.
Elevated Liver Enzymes

TYBLUME is contraindicated in females with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4)].  Discontinue TYBLUME if jaundice develops. Acute liver test abnormalities may necessitate the discontinuation of CHC use until the liver tests return to normal and CHC causation has been excluded. 

Liver Tumors

TYBLUME is contraindicated in females with benign or malignant liver tumors [see Contraindications (4)] . CHCs increase the risk of hepatic adenomas. An estimate of the attributable risk is 3.3 cases/100,000 CHC users. Rupture of hepatic adenomas may cause death from abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) CHC users. The attributable risk of liver cancers in CHC users is less than one case per million users.
The invention discloses a natto propolis ginkgo leaf health food and a preparation method thereof, relating to a health food and a preparation method thereof. The invention aims to solve the problems that an existing hypolipidemic health food is poor in healthcare effect, unreasonable in formula and unsatisfactory in healthcare effect. The natto propolis ginkgo leaf health food disclosed by the invention is prepared from the following components in parts by weight: 80-260 parts of natto flour, 5-155 parts of a ginkgo leaf extract and 15-175 parts of a propolis ethanol extract. The preparation method of the natto propolis ginkgo leaf health food comprises the steps of 1, weighing raw materials in parts by weight; and 2, uniformly mixing the raw materials, and adding auxiliary materials. Three types of raw materials combined together in the natto propolis ginkgo leaf health food disclosed by the invention have an effect of collaboratively reducing the blood fat through mutual cooperation, have a definite function of auxiliarily reducing blood fat and are significant in effect. The preparation method disclosed by the invention is used for preparing health foods.
Emotion regulation in adolescence is associated with health risk behaviors, including sex and substance use, and early onset of these behaviors represents a risk factor for negative health outcomes throughout life. Thus, interventions appropriate for early adolescence, when these behaviors commonly begin, are critical for prevention efforts. The research team has developed and tested a novel, engaging, and efficacious intervention that addresses emotion regulation, a theoretically important and under-researched factor associated with risk. The efficacy trial of this intervention, Project TRAC, showed that an intervention strategy using emotion regulation was significantly more successful than an active comparison condition on the primary target, delaying onset of sexual activity over a two and a half year follow-up, as well as on other risk behaviors, such as condom use, fighting, and partner violence. While efficacious, the current face-to-face, small group format of the program is a difficult model to sustain and implement on a larger scale. With a long-term goal toward dissemination, this two-year project will translate the emotion regulation components of this successful program for tablet-based delivery to enable it to reach a large audience in a format that can be related to a variety of health behavior education topics (e.g., sexual health, violence, substance use). For the proposed project, the Rhode Island Hospital/ Brown University research team will collaborate with Klein Buendel, a health communications technology company, to translate the emotion regulation content of Project TRAC for tablet computers. This translation, using well-established theoretical frameworks, will be approached in consultation with members of the target population (early adolescents) and experts in the field. After the intervention has been translated to a tablet form, ten adolescents will test the program to assess acceptability and usability. Finally, a small pilot study (n=100) will assess feasibility of the translated intervention and compare it to a waitlist control group.
A system and method for confirming that a medication administration device has been programmed with the correct medication administration parameters. A medical database carrier is used compare medication delivery parameters entered into a medication administration device to institutionally established guidelines or more widely accepted protocols to ensure that the medication is delivered in accordance to those guidelines. The medical database carrier may also be configured to communicate information regarding medication delivery and other patient information between a control system in communication with the care-giving facility's other information systems and a patient specific asset such as an infusion pump. The medical database carrier may be a smartcard, a PDA such as a PalmTM Pilot, laptop computer, pager, mobile phone, or other device capable of storing, processing and communicating information. The system may use either wired or wireless connections to communicate information between the components of the system. Figure 1.
A statement to patients and health care providers is included on the product's bottle label: ALERT: Find out about medicines that should NOT be taken with INVIRASE.

INVIRASE may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, nonprescription medication, or herbal products, particularly St. John's wort.

Patients should be informed that INVIRASE is not a cure for HIV infection and that they may continue to acquire illnesses associated with advanced HIV infection, including opportunistic infections. Patients should be advised that INVIRASE must be used in combination with ritonavir, which significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels. 

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving protease inhibitors and that the cause and long-term health effects of these conditions are not known at this time.

Patients should be told that the long-term effects of INVIRASE are unknown at this time. They should be informed that INVIRASE therapy has not been shown to reduce the risk of transmitting HIV to others through sexual contact or blood contamination.

Patients should be advised that INVIRASE administered with ritonavir should be taken within 2 hours after a full meal (see CLINICAL PHARMACOLOGY: Pharmacokinetics). When INVIRASE is taken without food, concentrations of saquinavir in the blood are substantially reduced and may result in no antiviral activity. Patients should be advised of the importance of taking their medication every day, as prescribed, to achieve maximum benefit. Patients should not alter the dose or discontinue therapy without consulting their physician. If a dose is missed, patients should take the next dose as soon as possible. However, the patient should not double the next dose.
All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
A total of 133 patients with type 2 diabetes participated in a 52 week, double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of linagliptin in patients with both type 2 diabetes and severe chronic renal impairment. Participants with an estimated (based on the four variables modified diet in renal disease [MDRD] equation) GFR value of <30 mL/min were eligible to participate in the study. Randomization was stratified by baseline HbA1c (≤8% and >8%) and background antidiabetic therapy (insulin or any combination with insulin, SU or glinides as monotherapy and pioglitazone or any other antidiabetics excluding any other DPP-4 inhibitors). For the initial 12 weeks of the study, background antidiabetic therapy was kept stable and included insulin, sulfonylurea, glinides, and pioglitazone. For the remainder of the trial, dose adjustments in antidiabetic background therapy were allowed. At baseline in this trial, 62.5% of patients were receiving insulin alone as background diabetes therapy, and 12.5% were receiving sulfonylurea alone.

After 12 weeks of treatment, linagliptin 5 mg provided statistically significant improvement in A1C compared to placebo, with an adjusted mean change of -0.6% compared to placebo (95% confidence interval -0.9, -0.3) based on the analysis using last observation carried forward (LOCF). With adjustments in antidiabetic background therapy after the initial 12 weeks, efficacy was maintained for 52 weeks, with an adjusted mean change from baseline in A1C of -0.7% compared to placebo (95% confidence interval -1.0, -0.4) based on analysis using LOCF.
The invention discloses a high-pressure injector in image inspection and an information integration method thereof. The high-pressure injector in the invention comprises a module which can carry out information interaction and processing with the RIS/PACS system. After the high pressure injector receives the message from the RIS/PACS system, the injector is initialized and the injection protocol is matched and extracted. After the examination is completed, a graphical injection information report is formed and sent to the RIS/PACS system in a DICOM Storage mode. The invention realizes the automatic cooperative work of the high-pressure injector in the image examination process at the background to the maximum extent in a message driving and data interaction mode, thereby practically reducing the workload of an examination technician, reducing errors and improving the working efficiency. Meanwhile, the contrast agent injection record is filed, and an important ring for the quality control of the radiographic image is added, so that the image inspection process is standardized, and the inspection quality is improved.
Use of an apoptosis-regulating substance (ARS) that modifies interaction of mitochondrial potassium channels (MK) with apoptosis-inducing and/or stimulating substances (AIS) to prepare a composition for treating or preventing diseases that involve excessive apoptosis. Use of at least one apoptosis-regulating substance (ARS) to prepare a composition for prevention and/or treatment of human or animal diseases which involve excessive apoptosis and/or are associated with appearance of apoptosis The new feature is that ARS modifies, especially inhibits, at least partly, interaction between a mitochondrial potassium channel (MK) and an apoptosis-stimulating and/or -inducing substance (AIS). An independent claim is also included for a method for discovery or identification of ARS. ACTIVITY : Nootropic; Neuroprotective; Antiparkinsonian; Cardiant; Vasotropic; Immunosuppressive; Antirheumatic; Hepatotropic; Antiapoptotic. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibits interaction between MK and natural proapoptotic compounds.
Provided is a melt granulated substance with a high grain size homogeneity. Furthermore, provided is a pharmaceutical composition using said melt granulated substance. Furthermore, provided is a melt granulated substance that has high content of active pharmaceutical ingredient. Furthermore, provided is a pharmaceutical composition using said melt granulated substance. An embodiment of the present invention provides granules that contain: an active pharmaceutical ingredient, a melt component, and a polymer, wherein the active pharmaceutical ingredient, the melt component and the polymer are bound together. Furthermore, the melt component is solid at ordinary temperature, and may have a melting point of 100℃ or less. The polymer is solid at ordinary temperature, and may have a glass transition point of 100℃ or less.
Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
The invention discloses a traditional Chinese medicine preparation for diminishing preputial edema. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 70-120 parts of flos carthami, 10-25 parts of musk, 70-120 parts of akebiaquinata, 30-60 parts of radix aconiti agrestis, 70-120 parts of lycopodium clavatum, 70-120 parts of sargentgloryvine stems, 70-120 parts of cassia twig, 70-120 parts of lysimachia christinae hance, 70-120 parts of white euphorbia kansui, 70-120 parts of climbing groundsel herb, 70-120 parts of elephantopus scaber, 5-15 parts of purple cathoclines and 18000-22000 parts of edible alcohol. According to the traditional Chinese medicine preparation disclosed by the invention, various medicinal materials with functions of dehumidifying and diminishing swelling, clearing away heat and toxic materials, dispelling wind and relieving pains, promoting blood circulation to remove blood stasis and the like are combined to exert the synergistic effects of the raw materials. The preparation is prepared by taking the edible alcohol as a medium. The traditional Chinese medicine preparation has a remarkable treatment effect on preputial edema and meanwhile has the sterilizing effect. The invention further provides a preparation method of the traditional Chinese medicine preparation.
Refractory ascites is one of the complications associated with portal hypertension in the cirrhotic patient. To date, its treatment consists of evacuating punctures, performed in day hospitalisation, whose frequency is adapted to the rate of ascites synthetis. Paracentesis, which does not affect the mechanisms of ascites formation, contributes to protein catabolism and undernutrition. They also have an inconvenience linked to the gesture, making frequent hospital stays necessary. For all these reasons, the patient's quality of life is diminished. The Alfapump® system is a new method for the treatment of refractory ascites. It is a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder, where ascites is eliminated by urinary tract.
PURPOSE: Idiopathic membranous nephropathy (IMN) is the most frequent global cause of nephrotic syndrome in non-diabetic people. In clinical practice, An effective and mild treatment for IMN patients with subnephrotic proteinuria has been adopted. Colquhounia root tablet (CRT) is a traditional Chinese medicine that is widely used in China to treat glomerulopathies. In this study, the effectiveness and safety of CRT in the treatment of IMN with subnephrotic proteinuria have been determined by reviewing the clinical records of 44 patients with IMN.
METHODS: Retrospective analysis of IMN patients with subnephrotic proteinuria treated with CRT in combination with ACEI/ARB or ACEI/ARB alone. The remission rate (complete or partial remission) was the main outcome observed, and proteinuria, estimated glomerular filtration rate (eGFR), serum albumin levels, and adverse effects were the secondary outcomes.
RESULTS: This clinical trial included 44 patients, and the overall remission rates at months 6, 9, and 12 after treatment were 68.2% versus 27.3% (p = 0.016), 72.7% versus 36.4% (p = 0.015), and 77.3% versus 36.4% (p = 0.006) in the treatment and control groups, respectively. The application of CRT treatment was an independent predictor of proteinuria remission (p = 0.024). In addition, in patients who were positive for phospholipase A2 receptor (PLA2R) antibodies, the overall remission rate was higher in the treatment group than in the control group after 9 months of treatment (75% versus 23.08%, p = 0.017).
CONCLUSION: This retrospective study illustrates that, based on supportive therapy, CRT could be effective in the treatment of IMN with subnephrotic proteinuria with a good safety profile at the same time.
Among the various suspected adverse effects of BPA on human health, studies on the possible effects of BPA on reproduction are limited. Animal and in vitro studies indicate that BPA exposure can lead to disrupted oocyte maturation, E2 suppression and early pregnancy loss caused by chromosomal abnormalities. In the woman, studies about the consequences of BPA exposure on reproduction is a very difficult task since gametogenesis in the woman spreads over decades, from the intra-uterine life where meiosis is initiated to the end of the reproductive period at menopause. Recently, a decreased survival of human foetal oocytes cultured in vitro in the presence of BPA has been shown suggesting that in vivo exposure in foetal life could affect the ovarian reserve. Furthermore, a negative association between urinary BPA level and serum peak E2, oocyte yield and blastocyst formation has been suggested on a limited population of women performing ART. These results suggest that, in adulthood, both quantity and quality of human oocytes could be affected by BPA exposures. The study aims to respond to these questions by evaluating the relationships between BPA exposition levels and embryo implantation rates (as a marker of oocyte quality) and anti-Mullerian hormon (AMH) levels (as a marker of ovarian reserve) in large population of young adult women performing ART. BPA exposure will be assessed at two times in both blood and urine: 1°) before the ovarian stimulation at the time of ovarian reserve tests and 2°) at the end of the ovarian stimulation the day of the ovarian puncture for IVF.
<P>PROBLEM TO BE SOLVED: To provide a color-changing cosmetic exhibiting excellent coloring state and color-changing state and to provide a cosmeticizing method using the cosmetic.  <P>SOLUTION: The color-changing cosmetic comprises one or more kinds of coloring agents, one or more kinds of developers and one or more color-changing agents. In the color-changing cosmetic, coloring occurs by mutual action between the coloring agents and developers and the color-changing agent stably exists without reacting with the coloring agents or developers and does not cause color change in formulation, and the change of color occurs by mutual action between color-changing agents and developers when used. The color-changing cosmetic comprises a first preparation containing one or more kinds of coloring agents and one or more kinds of developers and a second preparation containing one or more kinds of color-changing agents and changes color by mixing the first preparation with the second preparation when used. The cosmeticizing method comprises using the color-changing cosmetic.  <P>COPYRIGHT: (C)2004,JPO